U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011810) titled 'Axatilimab for Sclerotic Chronic Graft-versus-Host Disease' on June 02.
Brief Summary: This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell transplants. Sclerosis, while not associated with a higher risk of death, can lead to serious disabilities. Usual treatments for cGVHD can be associated with significant side effects and unsatisfactory outcomes. A monoclonal antibody, like axatilimab, is a...